Mineralys Therapeutics, Inc. (MLYS)

Market Cap	2.06B +362.7%
Revenue (ttm)	n/a
Net Income	-154.65M
EPS	-2.29
Shares Out	82.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,070,061
Open	25.65
Previous Close	25.73
Day's Range	24.90 - 25.86
52-Week Range	10.44 - 47.65
Beta	0.57
Analysts	Strong Buy
Price Target	48.67 (+94.52%)
Earnings Date	Mar 12, 2026

About MLYS

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. Its product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 10, 2023
• Employees: 51
• Stock Exchange: NASDAQ
• Ticker Symbol: MLYS
• Website: https://mineralystx.com

Analyst Summary

According to 6 analysts, the average rating for MLYS stock is "Strong Buy." The 12-month stock price target is $48.67, which is an increase of 94.52% from the latest price.

Price Target

$48.67

(94.52% upside)

Analyst Consensus: Strong Buy